



THE HOUSE OF REPRESENTATIVES

**STANDING COMMITTEE ON HEALTH, AGED CARE AND SPORT**

**Inquiry into approval processes for new drugs and novel medical technologies in Australia**

**PUBLIC HEARING  
Friday 7 May 2021**

**Corinthian Room  
SMC Conference & Function Centre, 66, Sydney**

<b>Time</b>	<b>Witness</b>
9.00 am	<p><b>Alexion Pharmaceuticals</b> Ms Sara Trafford-Jones, Vice President - South Cluster Lead (Brazil, Colombia, Turkey); General Manager Australian/New Zealand/China</p> <p><b>Kyowa Kirin Australia</b> Mr Simon Dawson, General Manager</p> <p><b>BioMarin Pharmaceutical Australia Pty Ltd</b> Dr Kathryn Evans, Area Director, Australia and New Zealand</p> <p><b>Recordati Rare Diseases Australia</b> Mr Anthony Shelton, General Manager</p>
10.00 am	<p><b>Takeda Pharmaceuticals Australia Pty Ltd</b> Mr Brad Edwards, General Manager, Australia and New Zealand</p> <p><b>Sanofi Australia and New Zealand</b> Ms Vanessa Xavier, Head of Market Access, Australia and New Zealand</p> <p><b>Varian Medical Systems Australasia Pty Ltd</b> Mrs Rebecca Cortiula, Senior Managing Director, Australasia</p> <p><b>Amicus Therapeutics</b> Dr Simon McErlane, Medical Director, APAC</p> <p><b>Myriad Genetics</b> Ms Andrea Tesoriero, Associate Director, Asia Pacific</p>
11.00 am	<b>Break</b>

11.30 am	<p><b>Roche Products Pty Limited</b> Mr Stuart Knight, General Manager</p> <p><b>Eli Lilly Australia Pty Ltd</b> Mr Benjamin Basil, President and General Manager Australia, New Zealand and North Asia-Pacific</p> <p><b>Novo Nordisk Pharmaceuticals, Oceania</b> Mr Jeppe Theisen, Vice President and General Manager</p> <p><b>Bayer Australia Limited</b> Mr Ashraf Al-Ouf, General Manager</p>
12.30 pm	<p><b>Luminesce Alliance - via teleconference</b> Acting Professor Michelle Farrar, Clinician representative from one of the Partners (UNSW) within the Luminesce Alliance Group</p> <p><b>Rare Cancers Australia</b> Mr Richard Vines, Chief Executive</p>
1.15 pm	<b>Break</b>
2.00 pm	<p><b>Australasian Society of Clinical Immunology and Allergy (ASCIA)</b> Professor Connie Katelaris AM, Chair, ASCIA Drug Allergy Committee and ASCIA HAE, CSU and CRNP Working Parties Ms Jill Smith, Chief Executive Officer</p> <p><b>Australasian Society of Clinical Immunology and Allergy (ASCIA) - via teleconference</b> Dr Theresa Cole, President Elect and co-Chair, ASCIA Immunodeficiency Committee Dr Melanie Wong, co-Chair, ASCIA Immunodeficiency Strategy Professor Jo Douglass, co-Chair, ASCIA Immunodeficiency Strategy Professor Michaela Lucas, President</p>
2.25 pm	<p><b>Australia and New Zealand Legal and Regulatory Affairs Committee of the International Society of Cell and Gene Therapy</b> Dr Gabrielle O'Sullivan, Co-Chair</p>
2.50 pm	<p><b>Australian Clinical Trials Alliance</b> Professor John Zalcberg, OAM, Chair</p>
3.15 pm	<p><b>The George Institute for Global Health</b> Professor Bruce Neal, Executive Director, Australia</p> <p><b>The University of New South Wales, Sydney</b> Professor Louisa Jorm, Professor, Faculty of Medicine; Director, Centre for Big Data Research in Health</p>